Want to see TSE:EPRX full AI Analyst Report?
EPRX Stock Chart & Stats
C$8.22
C$0.52(6.33%)
At close: 4:00 PM EDT
C$8.22
C$0.52(6.33%)
Day’s Range― - ―
52-Week RangeC$6.94 - C$12.86
Previous CloseN/A
Volume54.38K
Average Volume (3M)74.24K
Market Cap
C$631.46M
Enterprise ValueC$469.12
Total Cash (Recent Filing)C$133.44M
Total Debt (Recent Filing)C$1.84M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Nov 11, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding65,906,630
10 Day Avg. Volume63,163
30 Day Avg. Volume74,239
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)5.04
Price to Sales (P/S)0.00
P/FCF Ratio-13.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$23.57Price Target Upside186.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.84
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Drug-delivery PlatformDiffuSphere provides a differentiated delivery approach intended to sustain local treatment while reducing systemic exposure. If validated clinically, the platform could support multiple inflammatory indications and create longer-term product or licensing opportunities.
Low Leverage And Equity SupportVery low leverage limits interest and refinancing pressure while the larger equity base provides financial flexibility for clinical development. This strengthens resilience relative to highly indebted peers, although future funding remains necessary.
Durable Clinical Symptom ImprovementSustained symptom improvement through 52 weeks supports the potential durability of EP-104GI’s treatment effect in eosinophilic esophagitis. Longer-lasting benefit could improve its clinical differentiation and future commercial positioning if pivotal results confirm it.
Bears Say
Pre-revenue Business ModelWith no commercialized product revenue, Eupraxia lacks an operating revenue base to fund research, development, and corporate costs. Financial performance therefore depends on successful approvals and commercialization, leaving the business exposed to clinical and regulatory setbacks.
Worsening Operating Cash BurnIncreasing operating cash outflows indicate that development spending is consuming more capital before revenue begins. Continued burn reduces the duration of existing resources and raises the likelihood that additional financing will be required to advance the pipeline.
Dependence On Future FinancingThe securities shelf can improve access to capital, but it also highlights the need for external funding while operations remain unprofitable. Repeated equity issuance could dilute existing holders and increase dependence on capital-market conditions until products generate revenue.
Eupraxia Pharmaceuticals News
EPRX FAQ
What was Eupraxia Pharmaceuticals’s price range in the past 12 months?
Eupraxia Pharmaceuticals lowest stock price was C$6.94 and its highest was C$12.86 in the past 12 months.
What is Eupraxia Pharmaceuticals’s market cap?
Eupraxia Pharmaceuticals’s market cap is C$631.46M.
When is Eupraxia Pharmaceuticals’s upcoming earnings report date?
Eupraxia Pharmaceuticals’s upcoming earnings report date is Nov 11, 2026 which is in 83 days.
How were Eupraxia Pharmaceuticals’s earnings last quarter?
Eupraxia Pharmaceuticals released its earnings results on Aug 11, 2026. The company reported -C$0.308 earnings per share for the quarter, beating the consensus estimate of -C$0.312 by C$0.004.
Is Eupraxia Pharmaceuticals overvalued?
According to Wall Street analysts Eupraxia Pharmaceuticals’s price is currently Undervalued.
Does Eupraxia Pharmaceuticals pay dividends?
Eupraxia Pharmaceuticals does not currently pay dividends.
What is Eupraxia Pharmaceuticals’s EPS estimate?
Eupraxia Pharmaceuticals’s EPS estimate is -0.37.
How many shares outstanding does Eupraxia Pharmaceuticals have?
Eupraxia Pharmaceuticals has 65,906,630 shares outstanding.
What happened to Eupraxia Pharmaceuticals’s price movement after its last earnings report?
Eupraxia Pharmaceuticals reported an EPS of -C$0.308 in its last earnings report, beating expectations of -C$0.312. Following the earnings report the stock price went down -2.781%.
Which hedge fund is a major shareholder of Eupraxia Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:EPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eupraxia Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$23.57 (186.77% Upside)
C$23.57 (186.77% Upside)
Blogger Sentiment
Bullish
TSE:EPRX Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth C$207.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
516.50%
Trailing 12-Months
Company Description
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical trial, targeting both critical unmet medical needs and pain management for knee osteoarthritis. This promising candidate is also being developed for veterinary use, specifically for canine and equine osteoarthritis. Eupraxia's broader development portfolio includes EP-201, an antibiotic aimed at preventing post-surgical site infections, and EP-105, an extended-release anesthetic designed for extended post-operative pain relief. Furthermore, the company is actively developing product candidates for oncology applications. Established in 2011 and headquartered in Victoria, Canada, Eupraxia Pharmaceuticals Inc. was formerly known as Plaza Capital Partners Inc. until its renaming in May 2012.
EPRX Stock 12 Month Forecast
Average Price Target
C$23.57
▲(186.77% Upside)